A fluorescence-based sequence-specific primer PCR for the screening of HLA-B*57:01

被引：10

作者：

Giardina, Emiliano ^{[1
]}

Stocchi, Laura

Cuzzola, Valeria Foti ^{[2
]}

Zampatti, Stefania

Gambardella, Stefano ^{[3
]}

Patrizi, Maria Patrizia ^{[4
]}

Bramanti, Placido ^{[2
]}

Pirazzoli, Antonella ^{[5
]}

Novelli, Giuseppe ^{[6
]}

机构：

[1] Univ Roma Tor Vergata, Dept Biopathol, Div Genet, I-00133 Rome, Italy

[2] IRCCS Ctr Neurolesi Bonino Pulejo, Messina, Italy

[3] Bios Int, Rome, Italy

[4] Fdn Livio Patrizi, Rome, Italy

[5] ViiV Healthcare, Verona, Italy

[6] Univ Arkansas Med Sci & Cent Arkansas, Dept Internal Med, Fayetteville, AR USA

来源：

ELECTROPHORESIS | 2010年 / 31卷 / 21期

关键词：

Abacavir; Capillary electrophoresis; HLA-B*57:01; Pharmacogenetics; SSP-PCR; HUMAN-LEUKOCYTE ANTIGEN-B-ASTERISK-5701; ABACAVIR HYPERSENSITIVITY; HLA; MULTICENTER;

D O I：

10.1002/elps.201000283

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Abacavir (ABC) is an antiretroviral drug highly effective in the treatment of HIV, but its intake can cause severe hypersensitivity reaction (HSR). A strong association between HLA-B*57:01 and ABC HSRs was reported by several studies, which demonstrated that HLA-B*57:01 screening had a 100% negative predictive value and that it could accurately identify patients at high risk of ABC HSRs. We propose a new sequence-specific primer PCR assay based on fluorescence detection through CE which is highly sensitive, allowing the use of non-infective sources of DNA such as saliva and buccal swabs, in addition to blood and reproducible, allowing automation of the analytical process. The results of our study were first compared with a standard sequence-specific primer PCR technique and reported a concordance of 100%, and then a blind external validation further confirmed the accuracy of our method.

引用

页码：3525 / 3530

页数：6

共 19 条

[11]

Peyrière H, 2001, ANN PHARMACOTHER, V35, P1291

[12]

Phillips E, 2009, MOL DIAGN THER, V13, P1, DOI 10.2165/01250444-200913010-00001

[13]

Phillips EJ, 2009, CURR OPIN MOL THER, V11, P231

[14] HLA-B locus sequence-based typing [J].

Pozzi, S ;

Longo, A ;

Ferrara, GB .

TISSUE ANTIGENS, 1999, 53 (03) :275-281

[15] Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort study [J].

Rauch, A. ;

Nolan, D. ;

Martin, A. ;

McKinnon, E. ;

Almeida, C. ;

Mallal, Simon .

CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) :99-102

[16] High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients [J].

Saag, Michael ;

Balu, Rukmini ;

Phillips, Elizabeth ;

Brachman, Philip ;

Martorell, Claudia ;

Burman, William ;

Stancil, Britt ;

Mosteller, Michael ;

Brothers, Cindy ;

Wannamaker, Paul ;

Hughes, Arlene ;

Sutherland-Phillips, Denise ;

Mallal, Simon ;

Shaefer, Mark .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (07) :1111-1118

[17] The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV [J].

Schackman, Bruce R. ;

Scott, Callie A. ;

Walensky, Rochelle P. ;

Losina, Elena ;

Freedberg, Kenneth A. ;

Sax, Paul E. .

AIDS, 2008, 22 (15) :2025-2033

[18] First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America [J].

Young, Benjamin ;

Squires, Kathleen ;

Patel, Parul ;

Dejesus, Edwin ;

Bellos, Nicholaos ;

Bergerf, Daniel ;

Sutherland-Phillips, Denise H. ;

Liao, Qiming ;

Shaefer, Mark ;

Wannamaker, Palll .

AIDS, 2008, 22 (13) :1673-1675

[19] Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population [J].

Zucman, David ;

de Truchis, Pierre ;

Majerholc, Catherine ;

Stegman, Sophia ;

Caillat-Zucman, Sophie .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (01) :1-3

← 1 2 →